Abstract:A(3) Adenosine receptors (ARs) exhibit large species differences. Potent, selective agonists for rat (e.g. Cl-IB-MECA, 5) and human A(3) ARs (e.g. PENECA, 17, and analogs) have been developed during the past years. Potent, selective antagonists for human A(3) ARs include the imidazopurinones PSB-10 (28) and PSB-11 (29), the pyrazolotriazolopyrimidines MRE-3005F20 (38) and analogs, and the dihydropyridines (e.g. MRS-1334, 50). For rat A(3) ARs only moderately potent antagonists have been identified, such as the pyridine derivative MRS-1523 (51) and the flavonoid MRS-1067 (52), both of which exhibit only a low degree of selectivity versus the other AR subtypes. Selective antagonist radioligands for the human A(3) receptor, [(3)H]MRE-3008F20 and [(3)H]PSB-11, have been prepared, while A(3)-selective agonist radioligands are still lacking. Recent developments also include allosteric modulators, irreversibly binding antagonists, fluorescence-labelled agonists, partial agonists and inverse agonists for A(3)ARs. Site-directed mutagenesis and molecular modeling studies have been performed in order to obtain information about the ligand binding site and the process of receptor activation. A(3)Adenosine receptors have recently attracted considerable interest as novel drug targets. A(3) Agonists may have potential as cardioprotective and cerebroprotective agents, for the treatment of asthma, as antiinflammatory and immunosuppressive agents, and in cancer therapy as cytostatics and chemoprotective compounds. A(3) AR antagonists might be therapeutically useful for the acute treatment of stroke, for glaucoma, and also as antiasthmatic and antiallergic drugs, since A(3)receptors cannot only mediate antiinflammatory, but also proinflammatory responses. The future development of further pharmacological tools, including potent, selective antagonists for rat A(3) receptors and selective agonist radioligands for rat and human receptors will facilitate the evaluation of the (patho)physiological roles of A(3) receptors and the pharmacological potential of their ligands.

International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update

Progress in the pursuit of therapeutic adenosine receptor antagonists

Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development

A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists

Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives

Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity

Allosteric Modulation of Adenosine A2A Receptors as a New Therapeutic Avenue

A2B adenosine receptor signaling and regulation

Drugs targeting adenosine signaling pathways: A current view

Medicinal chemistry of adenosine A3 receptor ligands

Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays

Structural insights into ligand recognition, activation, and signaling of the α 2A adrenergic receptor

Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor

Adenosine and the Cardiovascular System

Machine Learning for Discovery of New ADORA Modulators

Neurogenetics of the Human Adenosine Receptor Genes: Genetic Structures and Involvement in Brain Diseases

Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain

Species dependence of A3 adenosine receptor pharmacology and function